- Home
- BOLT vs CLDI Comparison
BOLT vs CLDI Comparison
Compare BOLT & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOLT | CLDI |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOLT | CLDI |
|---|---|---|
| Price | $5.81 | $1.16 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 31.3K | ★ 71.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.41 | $1.10 |
| 52 Week High | $12.60 | $19.20 |
Technical Indicators
Market Signals| Indicator | BOLT | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 36.29 |
| Support Level | $5.50 | $1.12 |
| Resistance Level | $5.71 | $1.23 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 84.34 | 10.52 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.